Chemours (CC) Cash & Equivalents (2015 - 2026)

Chemours' Cash & Equivalents history runs 12 years deep, the most recent figure standing at $563.0 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 21.34% year-over-year to $563.0 million in Q1 2026; TTM through Mar 2026 was $563.0 million, a 21.34% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, down 99.72% from the prior year.
• Cash & Equivalents advanced to $563.0 million in Q1 2026 per CC's latest filing, from $2.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.2 billion in Q2 2022 and bottomed at $2.0 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $613.0 million (2025), against an average of $654.2 million.
• Biggest YoY gain for Cash & Equivalents was 3246.67% in 2025; the steepest drop was 99.72% in 2025.
• Year by year, Cash & Equivalents stood at $1.1 billion in 2022, then climbed by 9.17% to $1.2 billion in 2023, then tumbled by 40.73% to $713.0 million in 2024, then plunged by 99.72% to $2.0 million in 2025, then soared by 28050.0% to $563.0 million in 2026.
• Per Business Quant, the three latest CC Cash & Equivalents figures stand at $563.0 million (Q1 2026), $2.0 million (Q4 2025), and $613.0 million (Q3 2025).